Abstract
Background and objectives: The prognostic role of a disintegrin and metalloproteinase (ADAM) 17 has been widely assessed in gastric cancer. However, the results are inconsistent. We performed a meta-analysis to evaluate the prognostic significance of ADAM17 and its association with clinicopathological parameters. Methods: The databases of PubMed, Web of Science, and Embase were searched for relevant articles published up to April 2020. The reported hazard ratios (HRs) and odds ratios (ORs) and their corresponding 95% confidence intervals (CIs) were pooled to evaluate the strength of the association. Stata 12.1 was used to perform statistical analyses. Results: Seven studies, including 1757 patients, were screened for the meta-analysis. Compared with the high ADAM17 expression group, the pooled HR was higher in the low ADAM17 expression group (HR = 2.04, 95% CI 1.66–2.50; I2 = 18.1%; p = 0.299). High ADAM17 expression was also related to the tumor node metastasis (TNM) stages (OR = 4.09, 95% CI 1.85–9.04; I2 = 84.1%; p = 0.000), lymph node metastasis (OR = 3.08, 95% CI 1.13–8.36; I2 = 79.7%; p = 0.007), and ages (OR = 1.65, 95% CI 1.24–2.21; I2 = 0%; p = 0.692) of the gastric patients. Conclusions: This meta-analysis revealed that ADAM17 is a significant biomarker for poor prognosis in gastric cancer.
Highlights
Gastric cancer (GC) is one of the most common malignancies and the second leading cause of cancer-related death [1]
Web of Science, and Embase databases for the meta-analysis, 51 ofarticles them were of duplicates
1757 were participants included in this meta-analysis with a total of participants were included in this meta-analysis
Summary
Gastric cancer (GC) is one of the most common malignancies and the second leading cause of cancer-related death [1]. Stomach cancer has become a major public health issue. The disease imposes an economic burden, and affects quality of life for stomach cancer patients [2]. Gastric cancer is a multifactorial disease, and many factors can increase the risk of stomach cancer, such as Helicobacter pylori infection, family history, alcohol consumption, and smoking [3]. Determining an effective indicator to improve the prognosis is of great significance for improving the quality of life and reducing the mortality rates of GC patients. The prognostic role of a disintegrin and metalloproteinase (ADAM) 17 has been widely assessed in gastric cancer. We performed a meta-analysis to evaluate the prognostic significance of ADAM17 and its association with clinicopathological parameters. Results: Seven studies, including 1757 patients, were screened for the meta-analysis.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
